4.5 Article

Pemetrexed single agent in previously treated non-small cell lung cancer: A multi-institutional observational study

期刊

LUNG CANCER
卷 60, 期 2, 页码 240-245

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2007.10.008

关键词

non-small cell lung cancer; second-line; chemotherapy; pemetrexed

向作者/读者索取更多资源

Several drugs have been approved for the treatment of patients affected by advanced non-small. cell tung cancer (NSCLC) in progression after first line chemotherapy: Docetaxel, Pemetrexed and Erlotinib. Poor gain of survival has been demonstrated in randomised trials and patient characteristics predicting activity are poorly known yet. We evaluated the activity and toxicity of Pemetrexed, in a post-registration phase, to assess whether clinical benefits justify its employment in a second-line setting in routine clinical practice. Patients and methods: We collected data on patients with advanced NSCLC treated with Pemetrexed 500 mg/m(2) every 21 days, after progression to prior chemotherapy. Results: One hundred and sixty patients from 4 different Italian Institutions, treated with Pemetrexed, mostly as second-line therapy, were analysed. There was a predominance of mates versus females, adenocarcinoma versus other histologies; the median age was 63.6 years. The toxicity profile was extremely mild and the response rate (11.2% patients in complete or partial response) was similar to previous reports from the literature. The median overall survival, 12 months, was better than previously reported. Conclusion: Improved efficacy and mild toxicity observed in this clinically relevant patient population confirms Pemetrexed as an interesting choice in second-line treatment of NSCLC. Patient characteristics alone are not able to predict response to Pemetrexed. (C) 2007 Published by Elsevier Ireland Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据